Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
August 22 2022 - 11:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 5, 2022
________________
NOVO NORDISK A/S
(Exact name of
Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this
Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-________
Trading in Novo Nordisk shares
by board members, executives and associated persons
Bagsværd, Denmark, 5 August 2022 — This document discloses the
data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in
accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have
given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives
and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
1 |
Details of the person discharging managerial responsibilities/person
closely
associated |
a) |
Name of the Board
member/Executive/Associated Person |
Kasim Kutay |
2 |
Reason
for the notification |
a) |
Position/status |
Member of the Board of Directors
|
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details
of the issuer |
a) |
Name |
Novo Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details
of the transaction(s) |
a) |
Description of the financial instrument,
type of instrument,
|
ADRs |
Identification code
|
NVO |
b) |
Nature of the transaction |
Purchase of ADRs |
c) |
Price(s) and volume(s) |
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 758.55 |
116 ADRs |
|
|
|
|
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
116 ADRs
DKK 758.55 |
e) |
Date of the transaction |
2022-08-04 |
f) |
Place of the transaction |
New York Stock Exchange |
Page 2 of 2
Novo Nordisk is a leading global
healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious
chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access
to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets
its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New
York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
Further information
Media: |
|
|
Ambre Brown Morley |
+45 3079 9289 |
abmo@novonordisk.com |
Natalia Salomao Abrahao (US) |
+1 848 304 1027 |
niaa@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
David Heiberg Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Jacob Martin Wiborg Rode |
+45 3075 5956 |
jrde@novonordisk.com |
Mark Joseph Root (US) |
+1 848 213 3219 |
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet: www.novonordisk.com CVR
no:
24 25 67 90 |
|
|
Company announcement No 63 / 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: August 5, 2022 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Oct 2023 to Oct 2024